FTC Requests Public Comment on Petition from Sartorius Stedim Biotech S.A. for Agency Approval of Its Acquisition of Chromatography Equipment Business of Novasep Process SAS

Share This Page

For Your Information

The Federal Trade Commission is currently accepting public comments on an application by Sartorius Stedim Biotech S.A. for the Commission to approve its acquisition of the chromatography equipment business of Novasep Process SAS.

Sartorius was the FTC-approved divestiture buyer in 2020, when the FTC required Danaher Corporation to divest assets as a condition of acquiring General Electric’s biopharmaceutical business, which included chromatography assets. Sartorius agreed to obtain the Commission’s prior approval if it proposed to acquire Novasep’s chromatography business.

The FTC will publish Sartorius’s application in the Federal Register shortly. Instructions for filing comments appear in the published notice. Comments must be received 30 days after publication in the Federal Register. Once processed, they will be posted on Regulations.gov. After the comment period closes, the Commission will vote on whether to approve the application.

Contact Information

Media Contact: 
Office of Public Affairs
202-326-3707
Staff Contact: 
Lisa De Marchi Sleigh
Bureau of Competition Bureau of Competition
202-326-2535